收藏切换
Clinical observation of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease
收藏切换
Guohua SHI, Qin LIU, Wenyuan MA, Zanhuan CAI, Peiwen YU, Chunhui QI*
World Clinical Drug | 2022, 43(8) : 1039 - 1043
Less
收藏切换
World Clinical Drug | 2022, 43(8): 1039-1043
• Article •
Clinical observation of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease
Full
Guohua SHI, Qin LIU, Wenyuan MA, Zanhuan CAI, Peiwen YU, Chunhui QI*
Affiliations
  • Department of Internal Medicine, Shanghai Qingpu District Hospital of Traditional Chinese Medicine, Shanghai 201700, China
Published: 2022-08-10 doi: 10.13683/j.wph.2022.08.013
Outline
收藏切换
Objective

To explore the clinical efficacy of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease (COPD).

Methods

A total of 120 patients with stable COPD diagnosed and treated in our hospital were selected and randomly divided into the control group and the treatment group, 60 cases in each. The control group received conventional comprehensive treatment of western medicine, and the treatment group was treated with traditional Chinese medicine Bufei Yishen prescription on the basis of the control group. The traditional Chinese medicine (TCM) syndrome scores, pulmonary function index changes and adverse reactions were compared between the two groups after treatment.

Results

After treatment, the TCM syndrome scores of cough, expectoration and wheezing in the two groups were significantly lower than those before treatment (P<0.05), and those in the treatment groups were lower than those in the control group (P<0.05). After treatment, the percentage of forced vital capacity (FVC) in the predicted value, the predicted value of forced expiratory volume in the first second (FEV1), and the value of FEV1/FVC in the two groups were significantly higher than those before treatment (P<0.05), and those in the treatment groups were lower than those in the control group (P<0.05). The total incidence of adverse reactions in the control group was 16.67% (10/60), and 13.33% (8/60) in the treatment group, and there was no significant difference in the incidence of adverse reactions between the two groups (χ2=1.872, P=0.609).

Conclusion

Bufei Yishen prescription combined with western medicine on stable COPD can improve the symptoms of patients, which is safe and effective, suitable for clinical application.

Bufei Yishen prescription  /  chronic obstructive pulmonary disease  /  stable period  /  clinical efficacy
施国华, 刘琴, 马文苑, 蔡赞欢, 于佩雯, 戚春辉. 补肺益肾方治疗稳定期慢性阻塞性肺疾病患者临床疗效观察. 世界临床药物, 2022 , 43 (8) : 1039 -1043 . DOI: 10.13683/j.wph.2022.08.013
Guohua SHI, Qin LIU, Wenyuan MA, Zanhuan CAI, Peiwen YU, Chunhui QI. Clinical observation of Bufei Yishen prescription in the treatment of patients with stable chronic obstructive pulmonary disease[J]. World Clinical Drug, 2022 , 43 (8) : 1039 -1043 . DOI: 10.13683/j.wph.2022.08.013
Year 2022 volume 43 Issue 8
4
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.08.013
  • Receive Date:2021-12-30
  • Online Date:2026-11-19
  • Published:2022-08-10
Article Data
Affiliations
History
  • Received:2021-12-30
  • Revised:2022-05-27
Funding
Affiliations
    Department of Internal Medicine, Shanghai Qingpu District Hospital of Traditional Chinese Medicine, Shanghai 201700, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT